Viatris Inc. (VTRS)
$
8.29
-0.09 (-1.09%)
Key metrics
Financial statements
Free cash flow per share
1.5592
Market cap
10 Billion
Price to sales ratio
0.6952
Debt to equity
0.9238
Current ratio
1.6822
Income quality
-0.5867
Average inventory
4 Billion
ROE
-0.2060
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Viatris Inc. operates as a prominent healthcare company on a global scale, encompassing four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. Offering a diverse portfolio that includes prescription brand drugs, generic medications, complex generics, biosimilars, and active pharmaceutical ingredients (APIs), the company addresses various therapeutic areas, such as noncommunicable and infectious diseases. It specializes in biosimilars across oncology, immunology, endocrinology, ophthalmology, and dermatology, while providing APIs for antibacterial agents, central nervous system medications, antihistamines, cardiovascular treatments, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Additionally, the company supports patients through diagnostic clinics, educational seminars, and digital tools aimed at improving health management. Viatris makes its medicines available in a variety of formats including oral solids, injectables, complex dosage forms, and APIs, served to retail and pharmacy networks, wholesalers and distributors, payers, insurers, governments, and institutional clients. Distribution channels encompass pharmaceutical wholesalers and distributors, retailers, institutional pharmacies, mail-order and e-commerce pharmacies, alongside specialty pharmacies. The company's well-known product lineup features Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV, in addition to biosimilars such as Fulphila, Ogivri, Hulio, and SEMGLEE. The company recorded an operating income of $10,100,000.00 reflecting its earnings from core operations. It reported a substantial revenue of $14,739,300,000.00 demonstrating its strong market presence, while the weighted average number of diluted shares outstanding is 1,193,300,000.00 which indicates potential dilution effects. The company also reported selling, general, and administrative expenses of $4,425,600,000.00 shedding light on its operational overhead costs, culminating in a diluted EPS of -$0.53 which accounts for potential share dilution. In the stock market, the company presents an attractive opportunity as the stock is affordable at $8.29 making it suitable for budget-conscious investors. It enjoys a high average trading volume of 15,503,220.00 which indicates strong liquidity within the market. With a mid-range market capitalization of $9,729,807,200.00 Viatris Inc. is recognized as a steady performer. Operating within the Drug Manufacturers - Specialty & Generic industry, it plays a crucial role in shaping the overall market landscape. Furthermore, it belongs to the Healthcare sector, actively driving innovation and growth within the healthcare field.
Is Viatris Inc. (VTRS) a good investment?
Investing in Viatris Inc. (VTRS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Viatris Inc. (VTRS)'s stock forecast?
Analysts predict Viatris Inc. stock to fluctuate between $6.85 (low) and $13.55 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Viatris Inc.'s market capitalization?
As of 2025-05-23, Viatris Inc.'s market cap is $9,729,807,200, based on 1,173,680,000 outstanding shares.
How does Viatris Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Viatris Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Viatris Inc. pay dividends?
Viatris Inc. pays dividends. The current dividend yield is 5.79%, with a payout of $0.12 per share.
How can I buy Viatris Inc. (VTRS) stock?
To buy Viatris Inc. (VTRS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for VTRS. Place an order (Market, Limit, etc.).
What is the best time to invest in Viatris Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Viatris Inc. stock ever split?
Viatris Inc.'s last stock split was 3:2 on 2003-10-09.
How did Viatris Inc. perform in the last earnings report?
Revenue: $14,739,300,000 | EPS: -$0.53 | Growth: -1,262.28%.
Where can I find Viatris Inc.'s investor relations reports?
Visit https://www.viatris.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Viatris Inc.?
You can explore historical data from here
What is the all-time high and low for Viatris Inc. stock?
All-time high: $18.68 (2021-02-18) | All-time low: $6.85 (2025-04-10).
What are the key trends affecting Viatris Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=150358&wire=1&utm_campaign=14 or contact Joseph E. Levi, Esq.
globenewswire.com
PHILADELPHIA, May 27, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, inclusive (the “Class Period”).
accessnewswire.com
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. ("Viatris" or the "Company") (NASDAQ:VTRS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=150334&wire=1&utm_campaign=3 or contact Joseph E. Levi, Esq.
globenewswire.com
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=150327&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.
globenewswire.com
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit?
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=150300&wire=1&utm_campaign=30 or contact Joseph E. Levi, Esq.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=150281&wire=1&utm_campaign=27 or contact Joseph E. Levi, Esq.
accessnewswire.com
NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=150261&wire=1&utm_campaign=31 or contact Joseph E. Levi, Esq.
See all news
